Comparison of estimated human dose of 68Ga-MAA with 99mTc-MAA based on rat data

Shanehsazzadeh, Saeed; Lahooti, Afsaneh; Yousefnia, Hassan; Geramifar, Parham; Jalilian, Amir Reza

doi:10.1007/s12149-015-0997-z

Cited by 12 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…68 Ga is an attractive PET radioisotope with interesting physical properties and availability in the form of a 68 Ge/ 68 Ga generator[ 24 ] that make it a favorable option for radiopharmaceutical research. Therefore, various radiolabeled compounds have been developed using this radionuclide such as 68 Ga-DOTATATE,[ 25 ] 68 Ga-citrate,[ 26 ] and 68 Ga-ECC[ 15 ] showing the usefulness of this radioisotope in the detection and diagnosis of infections and inflammatory lesions using PET.…”

Section: Discussionmentioning

confidence: 99%

Human Dose Assessment of 68Ga-NODAGA-RGD-BBN Heterodimer Peptide based on Animal Data

Alirezapour

Amraee

Hosntalab

et al. 2022

Journal of Medical Physics

Self Cite

View full text Add to dashboard Cite

Aims: Calculation of the absorbed dose in human organs is one of the first steps for developing new radiopharmaceuticals. The aim of this study is to estimate the human absorbed dose of a newly developed 68 Ga-NODAGA-RGD-BBN radiolabeled compound. Materials and Methods: 68 Ga-NODAGA-RGD-BBN was prepared by varying different parameters at optimized conditions. The stability of the radiolabeled peptide in phosphate-buffered saline (PBS) and in human serum was evaluated for 120 min. Afterward, the biodistribution of the complex was assessed in normal and tumor-bearing mice, at least for 120 min postinjection. Finally, the human absorbed dose of 68 Ga-NODAGA-RGD-BBN was estimated based on mice data using Radiation Dose Assessment Resource and Spark method. Results: 68 Ga-NODAGA-RGD-BBN was produced with radiochemical purity of more than 98% (high-performance liquid chromatography/ radio thin layer chromatography (RTLC)) with high stability in PBS buffer and in human serum at least for 2 h. The complex demonstrated high uptake in gastrin-releasing peptide receptor-expressing tumors compared to other nontarget organs. Furthermore, the dose assessment for the complex showed that the kidneys receive the highest absorbed dose in comparison with other organs. Conclusion: The result of this study showed that 68Ga-NODAGA-RGD-BBN is an effective and radiolabeled ligand for tumor detection, however more studies are still needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Human Dose Assessment of 68Ga-NODAGA-RGD-BBN Heterodimer Peptide based on Animal Data

Alirezapour

Amraee

Hosntalab

et al. 2022

Journal of Medical Physics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Indeed, absence or presence of SnCl 2 had no impact on labeling efficiency ( 132 ). Unfortunately, despite initial promises and possible lower-dose delivery to critical organs, 68 Ga-MAA or 68 Ga-HSA has never broken through ( 166 ).…”

Section: Cold Kitsmentioning

confidence: 99%

Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?

Lepareur

2022

Front. Med.

View full text Add to dashboard Cite

Over the last couple of decades, gallium-68 (68Ga) has gained a formidable interest for PET molecular imaging of various conditions, from cancer to infection, through cardiac pathologies or neuropathies. It has gained routine use, with successful radiopharmaceuticals such as somatostatin analogs ([68Ga]Ga-DOTATOC and [68Ga]GaDOTATATE) for neuroendocrine tumors, and PSMA ligands for prostate cancer. It represents a major clinical impact, particularly in the context of theranostics, coupled with their 177Lu-labeled counterparts. Beside those, a bunch of new 68Ga-labeled molecules are in the preclinical and clinical pipelines, with some of them showing great promise for patient care. Increasing clinical demand and regulatory issues have led to the development of automated procedures for the production of 68Ga radiopharmaceuticals. However, the widespread use of these radiopharmaceuticals may rely on simple and efficient radiolabeling methods, undemanding in terms of equipment and infrastructure. To make them technically and economically accessible to the medical community and its patients, it appears mandatory to develop a procedure similar to the well-established kit-based 99mTc chemistry. Already available commercial kits for the production of 68Ga radiopharmaceuticals have demonstrated the feasibility of using such an approach, thus paving the way for more kit-based 68Ga radiopharmaceuticals to be developed. This article discusses the development of 68Ga cold kit radiopharmacy, including technical issues, and regulatory aspects.

show abstract

“…Accordingly, 68 Ga and 18 F can be used as alternatives in nuclear imaging. Physical properties and cyclotron-independent availability of gallium-68 from 68 Ge/ 68 Ga generator with low cost led to gallium-68 being proposed as a new PET element (3) . 68 Ga decays to an excited state at 1077 keV (3%) and has a half-life of 67.71 minutes (4) .…”

Section: Introductionmentioning

confidence: 99%

Estimation of human absorbed dose of 68-Ga-Citrate based on biodistribution data in rats: Comparison with 67-Ga-Citrate

Habibi,

Faghihi,

Zolghadri

et al. 2022

Int J Radiat Res

View full text Add to dashboard Cite

Background:In recent years, Gallium-68 citrate has become known as an alternative radioisotope in nuclear medicine. As for its influences, 68 Ga-based tracers have already been proposed as agents for positron emission tomography. In this research, the values of human absorbed dose for 68 Ga-citrate and 67 Ga-citrate were estimated using the medical internal radiation dose method based on biodistribution data in rats. Materials and Methods: 68 Ga/ 67 Ga-citrate was prepared from eluted 68 Ga/ 67 Ga-Cl 3 and sodium citrate under multiple reaction forms. The biodistribution of 68 Ga/ 67 Gacitrate radiolabeled compounds was investigated by dissection of five male rats at specific times after injection. The organs of the rats were removed and counted. Percentage of injected dose per gram was determined for each rat organ and the human absorbed dose was extrapolated using the rats' data. Results: The results of estimating the human absorbed dose illustrate that 68 Ga-citrate caused a much lower human absorbed dose compared with 67 Ga-citrate. Conclusion: According to the results, it may be concluded that 68 Ga-citrate, despite the better quality of PET imaging, is much safer in terms of absorption dose compared with 67 Ga-citrate, and from this point of view, it is a more appropriate agent for imaging applications.

show abstract

Comparison of estimated human dose of 68Ga-MAA with 99mTc-MAA based on rat data

Abstract: Since the (99m)Tc-MAA remains longer than ⁶⁸Ga-MAA in the lung and ⁶⁸Ga-MAA has good image qualities and results in lower amounts of dose delivery to the critical organs such as gonads, red marrow, and adrenals, the use of ⁶⁸Ga-MAA is recommended.

Cited by 12 publications

References 32 publications

Human Dose Assessment of 68Ga-NODAGA-RGD-BBN Heterodimer Peptide based on Animal Data

Human Dose Assessment of 68Ga-NODAGA-RGD-BBN Heterodimer Peptide based on Animal Data

Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?

Estimation of human absorbed dose of 68-Ga-Citrate based on biodistribution data in rats: Comparison with 67-Ga-Citrate

Contact Info

Product

Resources

About